Thermo Fisher Scientific (NYSE:TMO) said it is adding early development work for oral solid dose therapies to its site in Bourgoin, France.
The expansion will allow for early drug development through commercial manufacturing.
The company noted that Bourgoin is its center of excellence in Europe for oral solid dose end-to-end drug product development and high potent substance handling.
“Expanding our capabilities in France is a further investment in our global oral solid network that will allow us to further forge partnerships with customers who depend on our capabilities for the development and commercial production of lifesaving drugs for their patients,” said Leon Wyszkowski, president of pharma services commercial operations.
TMO said that in 2021, the French government’s provided a grant to help with the early development hub. Construction work started in Q1 2022 enabling first activities to be launched in June 2022.
In addition to expanded good manufacturing practices (GMP) facilities, the early development hub includes a 4.6K square feet research and development facility for pre-clinical, non-GMP operations.
Thermo Fisher said that the expansion in Bourgoin builds on its investments in small molecule solutions, including oral solid dose development and production services in Bend, Ore.; Greenville, N.C.; Cincinnati, Ohio; Manatí, Puerto Rico; Toronto; Whitby, Canada; and Milton Park, U.K.